Draig Therapeutics closes an oversubscribed $65 million Series B round led by Deep Track Capital to accelerate the development of neuropsychiatric therapies.
Janus Henderson InvestorsMarshall WaceBritish Business BankJefferson Life SciencesDeep Track Capital
Description
Draig Therapeutics, a clinical-stage biopharmaceutical company, has closed an oversubscribed $65 million Series B financing. This round aims to accelerate the development of specific AMPA and GABAA receptor modulators for neuropsychiatric disorders. The financing was led by Deep Track Capital, with participation from several notable investors.
Company Information
Company
Draig Therapeutics
Location
Cardiff, Wales, United Kingdom
About
Draig Therapeutics is a clinical-stage company focused on transforming the treatment of neuropsychiatric diseases through its innovative pipeline of next-generation therapies. The company targets core neurotransmission pathways that play a critical role in these complex disorders. Its lead candidate, DT-101, aims to provide more effective treatments for Major Depressive Disorder. Draig was formed through a collaboration with Cardiff University's Medicines Discovery Institute.
Fundz sees it the moment Draig Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
CardiffBiotechnologyHealth CareTherapeuticsresearch